clinical trial · NCT05694819
Darolutamide in Patients With Androgen Receptor-Positive Salivary Gland Carcinoma (DISCOVARY)
National Cancer Center Hospital East·phase2·completed·n = 57
Salivary Gland CancerDarolutamideGoserelin
brief summary
This study is an open-label phase 2 study to evaluate the safety and efficacy of Darolutamide monotherapy in patients with androgen receptor-positive salivary gland carcinoma. Moreover, this study will evaluate the safety and efficacy of Darolutamide and Goserelin combination in patients with androgen receptor-positive salivary gland carcinoma.
started
Apr 17, 2020
primary completion
Aug 9, 2024
completion
Mar 23, 2026
last updated
Apr 8, 2026
official title
Phase II Study of Darolutamide (ODM-201) in Patients With Androgen Receptor-positive Salivary Gland Carcinoma (Discovary Study)
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol